Fig. 6. Transcranial magnetic stimulation (TMS) treatment increases Nb-Ft-TRPV1^Ca2+ mediated motor freezing and calcium transients in dorsal striatum.

A. Schema of the TMS set up and A2a-Cre mice with bilateral injection of the double-floxed Cre-dependent AAV vector expressing the Nb-Ft-TRPV1^Ca2+ or mCherry under the control of the JET promoter (red) combined with double floxed Cre-dependent AAV vector expressing GCaMP6s under the control of the Syn promoter (green) in dorsal striatum. B. Activity trace example of altered motor activity during baseline (left) and TMS (right) treatment in an mCherry mouse (blue), and Nb-Ft-TRPV1^Ca2+ mouse (red). Distance ambulated during baseline (left) and TMS (right) treatment in the C. mCherry group (blue), and D. Nb-Ft-TRPV1^Ca2+ group (red). (n=4–5; data presented as the mean ± SEM in grey.). E. Average distance during baseline and TMS treatment in mCherry (blue) and Nb-Ft-TRPV1^Ca2+ groups. F. Mean fluorescence during baseline in Nb-Ft-TRPV1^Ca2+ (red) and mCherry (blue) mice (n=3; data presented as the mean ± SEM). G. Mean fluorescence during 20 seconds of TMS triggers every 2 seconds in Nb-Ft-TRPV1^Ca2+ (red) and mCherry (blue) mice (n=3–4; data presented as the mean ± SEM). H. Grouped bar graph of Nb-Ft-TRPV1^Ca2+ (red) and mCherry (blue) mice during baseline, and 20 seconds of TMS triggers every 2 seconds (n=3–4). Error bars show SEM. ** represents p value < 0.01, *** represents p value < 0.001 with two-tailed, unpaired (or paired when baseline vs TMS comparison were done) t-test with Welch’s correction.